NEW YORK, Nov. 18, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN).Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/?id=112073&from=4C ...

NEW YORK, Nov. 16, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

Acquisition Details - Elanco Animal Health acquired a contract manufacturing facility and related assets in Speke, UK, previously owned by TriRx Speke Ltd, which was under trading administration [1] - The acquisition cost $25 million in cash at closing, with the company providing interim funding during the administration process [2] - The Speke facility is critical for producing farm animal product lines, generating approximately $160 million to $180 million in annual farm animal revenue, primarily outside the US [2] Strategic Importance - The Speke facility plays a vital role in Elanco's global supply chain for key farm animal products, securing production continuity [2] - Elanco previously held a long-term supply agreement with TriRx Speke Ltd, and the acquisition ensures control over this critical component of its supply chain [2] Financial Impact - Elanco expects an adjusted EBITDA headwind of $25 million to $35 million in 2025 due to the acquisition, primarily impacting gross profit [3] - The company will assume site ownership immediately and work closely with site leadership to support operations [3] Company Overview - Elanco Animal Health is a global leader in animal health, with nearly 70 years of heritage, focusing on innovating and delivering products and services for farm animals and pets [4] - The company is committed to improving animal health and making a meaningful impact on local and global communities, driven by its vision of "Food and Companionship Enriching Life" [4]

NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

NEW YORK, Nov. 14, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN).Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/?id=111738&from=4  ...

PHILADELPHIA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Elanco Animal Health Inc. (“Elanco” or the “Company”) (NYSE: ELAN). The lawsuit has been filed on behalf of purchasers of ELANCO securities between November 7, 2023 and June 26, 2024, inclusive (the “Class Period”). CLICK HERE TO LEARN MORE ABOUT THIS LAWSUIT. Investors who purchased or acquired ELANCO securities during the Class Period may, no later than DECEMBER 6, 2024, seek to be appointed as a lead ...

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN). Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/?id=111425& ...

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

Core Insights - Elanco Animal Health has appointed Dr. Stacey Ma to its Board of Directors, effective immediately, enhancing the company's expertise in biopharmaceutical development and manufacturing [1][2]. Company Overview - Elanco Animal Health is a global leader in animal health, dedicated to innovating and delivering products and services to prevent and treat diseases in farm animals and pets, with nearly 70 years of heritage in the industry [6]. Leadership and Expertise - Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufacturing, currently serving as Executive Vice President at Gilead Sciences, where she oversees product and portfolio strategy, technical development, supply chain, quality, CMC regulatory, and manufacturing operations [3][5]. - Dr. Ma has held leadership positions at Sana Biotechnology and Genentech/Roche, contributing significantly to product development and technical innovation [3][4]. Strategic Contributions - Dr. Ma's expertise in Chemistry, Manufacturing and Controls (CMC) strategy and technical operations is expected to be valuable as Elanco transitions significant products from research to manufacturing scale-up [5]. - Her role will also support Elanco's Innovation, Portfolio and Productivity (IPP) strategy, aimed at developing a consistent flow of high-impact innovations in the company's next-generation pipeline [5].

NEW YORK, Nov. 10, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...